The comprehensive report published by Persistence Market Research offers an in-depth intelligence related to the various factors that are likely to impact the demand, revenue generation, and sales of the Plaque Psoriasis Treatment Market. In addition, the report singles out the different parameters that are expected to influence the overall dynamics of the Plaque Psoriasis Treatment Market during the forecast period 2017 2025.

As per the findings of the presented study, the Plaque Psoriasis Treatment Market is poised to surpass the value of ~US$ XX by the end of 2029 growing at a CAGR of ~XX% over the assessment period. The report includes a thorough analysis of the upstream raw materials, supply-demand ratio of the Plaque Psoriasis Treatment in different regions, import-export trends and more to provide readers a fair understanding of the global market scenario.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.persistencemarketresearch.co/samples/16069

The report segregates the Plaque Psoriasis Treatment Market into different segments to provide a detailed understanding of the various aspects of the market. The competitive analysis of the Plaque Psoriasis Treatment Market includes valuable insights based on which, market players can formulate impactful growth strategies to enhance their presence in the Plaque Psoriasis Treatment Market.

Key findings of the report:

The report aims to eliminate the following doubts related to the Plaque Psoriasis Treatment Market:

Get Access To TOC Covering 200+ Topics athttps://www.persistencemarketresearch.co/toc/16069

market players are also exploring the developing market. Novartis launched its Cosentyx in Japan for the treatment of psoriasis arthritis in adults who are not adequately responding to systemic therapy.

Plaque Psoriasis Treatment Market: Market Players

Company manufacturer is converting innovative research into a new therapy by constantly investing in research activities. The number of drugs approved for plaque psoriasis is constantly increasing the number of treatment options for the physician and patients. Eli Lillys interleukin inhibitor was approved by the FDA, second molecule to be approved after Novartis Cosentyx.

Some of the plaque psoriasis treatment market contributors are Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira Inc., Novartis, Galectin Therapeutics, Cellceutix Corporation and Biogen Inc., Bayer.

In order to get a strategic overview of the market,Access Research Methodology Prepared By Experts athttps://www.persistencemarketresearch.co/methodology/16069

Reasons to buy from PMR

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

Persistence Market Research

305 Broadway, 7th Floor

New York City, NY 10007

United States

Ph.no. +1-646-568-7751

This post was originally published on Info Street Wire

Follow this link:

Plaque Psoriasis Treatment Market Expansion Projected to Gain an Uptick During 2017 2025 - Info Street Wire

As I searched online for Christmas presents for my loved ones recently, I browsed selections of pre-made gift kits. Many of them were bath or skin care based. I saw adorable bubble bath sets for children, makeup and nail kits, and baskets of soaps and creams marketed to young men and women.

Skin care products can make lovely gifts. I bought a unicorn tumbler full of bath bombs for my young cousin. But as I shopped, I thought about how I wouldnt buy gifts like these for myself. As someone withjuvenile-onset psoriatic arthritis, I would worry that they might flare my skin. I realized many of these gifts wouldnt be suitable for kids or young adults with juvenile rheumatic conditions.

Additionally, conditions such as systemic arthritis, dermatomyositis, scleroderma, psoriatic arthritis, and lupus can cause rashes, lesions, and other skin issues, which can be further irritated by skin care products.

Those with skin conditions cant usually tolerate the ingredients used in pre-made bath sets and makeup kits. Items such as bath bombs are not recommended for those with particular skin conditions. Other products may be drying and irritating to those with sensitive or inflamed skin.

But that doesnt mean you have to avoid giving pampering gifts altogether. Many kids with juvenile arthritis benefit from the soothing effects of a warm bathand the confidence boost of wearing makeup. Instead, when choosing a gift, consider the products quality.

If youre thinking of giving soaps, makeup, and lotions as gifts dont be afraid to ask the childs parents which products they use. And stick to those brands. Dont be misled by product labels containing words like natural, healing, or even psoriasis-friendly. While the claims might be valid, its best to stick to products that the family already trusts the brands they use are likely either doctor recommended or theyve discovered them after much trial and error.

Quality is essential for those living with chronic skin conditions. Dont be surprised if the products and brands that the person uses are a little expensive. You dont need to break your budget, but remember that its better to choose quality over quantity. A trusted eye shadow palette with one or two colors is worth much more than another with multiple shades that may irritate the skin.

You might also consider gifting skin care accessories such as makeup brushes or sponges, or a cosmetic bag to keep products in.

You could put together a custom-made bath kit. For younger kids, a bath caddy filled with bath toys and crayons, a hooded towel, a brush and comb, and fun, colored puffs. Older kids and teens might prefer bathrobes, slippers, eye pillows, spa socks, and candles or essential oils. I like this idea because you can pick and choose each item and customize it to the recipient.

Ive received lots of bath and beauty products in the past. Many of them came from my parents, who knew how careful I needed to be with skin products. Im always extremely appreciative of the lotions, makeup, and perfumes they gift, particularly as they can be pricey.

Sometimes Ive received products that I didnt feel comfortable using. But I accepted them with a smile and a genuine thank you. Im grateful for the gift of someone thinking of me, taking the time to buy me a gift, and wrap it up.

***

Note: Juvenile Arthritis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Juvenile Arthritis News, or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to juvenile arthritis.

Elizabeth Medeiros is a young adult who has dealt with juvenile arthritis since she was a small child. However, her pain hasnt stopped her from working on a product design degree in Boston. Her passion is to create products that make life easier for the chronically ill, such as shoes and walking canes. When shes not in class, Elizabeth enjoys writing about how shes coped with arthritis at such a young age. You can find more of her writings at ArthritisGirl.Blogspot.com and on Instagram @GirlWithArthritis.

Read this article:

Think Twice When Choosing Skin Care Products as Gifts for Kids with JA - Juvenile Arthritis News

While there's no cure for the annoying skin condition psoriasis it's easy to soothe with some cream on your arms and legs - but what about relieving your itchy scalp?

One woman took to the Facebook group Mas on a Mission to ask for help as she is being "driven demented" with the genetic condition, and other women were quick to share their home remedies.

Many of them recommended coconut oil, which has anti-inflammatory properties and can help easy psoriasis pain.

"Coconut oil with lemon juice is very good," one said, while another added: "Coconut oil works for me."

"I put coconut oil in once a week and leave overnight," said a third, reports RSVPLive.

Others swore by tea tree oil, which is said to have antibacterial,antiviral and antifungal properties.

"I found tea tree oil great, I put a few drops in the bath," one suggested.

"I get it when I'm stressed and the best thing for me is a few drops of tea tree oil in my shampoo bottle!" added another.

Another remedy was the anti-dandruff shampoo Nizoral.

One group member said: "I use Nizoral shampoo I get it on prescription from doctor and it's brill!"

Other options include getting prescription medication which contains such active ingredients as coal tar and salicylic acid.

Many psoriasis suffers also find sunlight can help, particularly if you have thin hair.

More:

Mum's clever hack for getting rid of psoriasis on your scalp - Nottinghamshire Live

A mum has shared a brilliant way to get rid of psoriasis from your scalp.

Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales.

These patches normally appear on your elbows, knees, scalp and lower back, but can appear anywhere on your body.

Most people are only affected with small patches. In some cases, the patches can be itchy or sore.

Psoriasis affects around 2% of people in the UK. It can start at any age, but most often develops in adults under 35 years old, and affects men and women equally.

One woman took to the Facebook group Mas on a Mission to ask for help as she is being "driven demented" with the condition, and other women were quick to share their home remedies.

Many of them recommended coconut oil, which has anti-inflammatory properties and can help easypsoriasispain, reports RSVPLive.

"Coconut oil with lemon juice is very good," one said, while another added: "Coconut oil works for me."

"I put coconut oil in once a week and leave overnight," said a third.

Others swore by tea tree oil, which is said to have antibacterial,antiviraland antifungal properties.

"I found tea tree oil great, I put a few drops in the bath," one suggested.

"I get it when I'm stressed and the best thing for me is a few drops of tea tree oil in my shampoo bottle!" added another.

Another remedy was the anti-dandruff shampoo Nizoral.

One group member said: "I use Nizoral shampoo I get it on prescription from doctor and it's brill!"

Read more here:

Mum's brilliant trick to get rid of psoriasis from your scalp - and people are swearing by it - Birmingham Live

COPENHAGEN, Denmark, December 18, 2019 / B3C newswire / -- MC2 Therapeutics, an emerging pharmaceutical company focused on novel PAD Technology based topical therapies for chronic inflammatory conditions, today announced that its EU Phase 3 trial (n=490) on the companys investigational drug, Wynzora Cream, met its primary endpoint and that a Marketing Authorization Application (MAA) is now in preparation for H1 2020.

Wynzora Cream (calcipotriene and betamethasone dipropionate, 0.005%/0.064% w/w) was studied in adult patients with plaque psoriasis and compared to Daivobet Gel (marketed in the US as Taclonex Topical Suspension) and cream vehicle.

Top-line data demonstrate that:

Wynzora Cream has statistically significantly greater treatment efficacy compared to Daivobet Gel

Wynzora Cream has statistically significantly better patient reported outcomes compared to Daivobet Gel

Wynzora Cream demonstrates a favorable safety profile

We continue to be impressed by the performance of Wynzora Cream in clinical trials. With a PGA treatment success of 52% and 68% reduction in mPASI and a very favorable safety profile, Wynzora Cream is delivering on its promise to provide high comfort to physicians and patients in treating plaque psoriasis. stated Jesper J. Lange, CEO of MC2 Therapeutics and added: Wynzora Cream takes the treatment experience in daily routines to a new level. Our PAD Technology has enabled an aqueous cream formulation that is designed for high convenience in daily routines illustrated by the positive patient reported treatment convenience and quality of life outcomes in our Phase 3 trials. This is a key component of treatment in real life settings.

MC2 Therapeutics is seeking to upgrade the treatment experience for patients having chronic inflammatory diseases including plaque psoriasis. Enabled by PAD Technology, Wynzora Cream has been developed to provide physicians and patients high comfort on relief of psoriasis symptoms with favorable safety and convenience in daily routines. A once-daily, non-greasy product that quickly absorbs into the skin allowing patients to comfortably put on clothes, go to bed or engage in other physical and social activities within a few minutes after application.

The EU Phase 3 data is an important step in the global development of Wynzora Cream. MC2 Therapeutics recently announced FDAs acceptance of its New Drug Application on Wynzora Cream with July 20th, 2020 as the PDUFA action date.

About the Wynzora Cream Phase 3 TrialThis Phase 3, randomized, multicenter, investigator-blind, parallel-group trial evaluated the efficacy and safety of Wynzora Cream compared to Wynzora vehicle and the active comparator Daivobet Gel in patients with psoriasis vulgaris. The trial enrolled 490 patients at 32 clinical centers across Germany, Poland and Czech Republic. Patients applied trial medication topically once daily for eight weeks.

Data from the trial will be presented at upcoming clinical conferences. Global development of Wynzora Cream will continue and MC2 Therapeutics plans to submit a MAA in EU in the first half of 2020.

About Wynzora CreamWynzora Cream is the first cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis. Wynzora Cream is based on PAD Technology, which uniquely enables stability of both calcipotriene and betamethasone dipropionate in a convenient aqueous formulation. In the Phase 3 trials conducted at multiple sites in the US and the EU, Wynzora Cream has demonstrated a statistically significantly greater efficacy compared to Taclonex Topical Suspension and Daivobet gel. The unique combination of significant clinical efficacy, a favorable safety profile and high convenience of Wynzora Cream holds promise to increase treatment adherence and overall patient satisfaction in topical treatment of plaque psoriasis in the real-world setting.

About MC2 Therapeutics A/SMC2 Therapeutics is a privately held pharmaceutical company focused on topical therapies for chronic inflammatory conditions. Using its proprietary PAD Technology MC2 Therapeutics is developing a pipeline of novel innovative topical therapies designed for unique patient experiences.

For additional information on MC2 Therapeutics Group, please visit http://www.mc2therapeutics.com

Next events

Jesper J. Lange, CEO will present at Dermatology Summit, San Francisco, January 12th, 2020JP Morgan Healthcare Conference, San Francisco, January 13th - 16th, 2020Winter Clinical, Hawaii, January 16th 19th, 2020AAD, Denver, March 20th 24th, 2020

Contact

MC2 Therapeutics A/SLonni Goltermann, EA to the CEO +45 2018 1111 This email address is being protected from spambots. You need JavaScript enabled to view it.

Keywords: Humans; betamethasone dipropionate, calcipotriol; calcipotriene; Prostaglandins A; Patient Satisfaction; Drug Users; Betamethasone; Calcitriol; betamethasone-17,21-dipropionate; Xamiol gel; Taclonex; Daivobet; Psoriasis; Drug Combinations; Treatment Outcome; Marketing

Published by B3C newswire and shared through Newronic

Here is the original post:

MC2 Therapeutics Announces Positive Top-line Results from EU Phase 3 Head-to-Head Trial Comparing Wynzora Cream to Daivobet Gel in Patients with...

Los Angeles, United State, 24 December 2019 The report titled Global Psoriasis Treatment Market is one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Psoriasis Treatment market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Psoriasis Treatment market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Psoriasis Treatment market is carefully analyzed and researched about by the market analysts.

Global Psoriasis Treatment Market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

Top Key Players of the Global Psoriasis Treatment Market : Novartis International AG, Johnson & Johnson, Pfizer Inc., Merck and Co. Inc., AbbVie and Amgen, Eli Lilly

Download Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) : https://www.qyresearch.com/sample-form/form/703094/global-psoriasis-treatment-industry-research-report-growth-trends-and-competitive-analysis-2018-2025

The Essential Content Covered in the Global Psoriasis Treatment Market Report :

* Top Key Company Profiles.* Main Business and Rival Information * SWOT Analysis and PESTEL Analysis * Production, Sales, Revenue, Price and Gross Margin* Market Share and Size

Global Psoriasis Treatment Market Segmentation By Product :TNF Inhibitors, Phosphodiesterase Inhibitors, Interleukin Blockers, Others

Global Psoriasis Treatment Market Segmentation By Application :Oral, Tropical, Injectable

In terms of region, this research report covers almost all the major regions across the globe such as North America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. WhilePsoriasis Treatment Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets.Psoriasis Treatment Market in South, America region is also expected to grow in near future.

Key questions answered in the report

Research Methodology

We provide detailed product mapping and analysis of various market scenarios. Our analysts are experts in providing in-depth analysis and breakdown of the business of key market leaders. We keep a close eye on recent developments and follow latest company news related to different players operating in the global Psoriasis Treatment market. This helps us to deeply analyze companies as well as the competitive landscape. Our vendor landscape analysis offers a complete study that will help you to stay on top of the competition.

Table of Contents

1 Report Overview1.1 Research Scope1.2 Major Manufacturers Covered in This Report1.3 Market Segment by Type1.3.1 Global Psoriasis Treatment Market Size Growth Rate by Type1.3.2 TNF Inhibitors1.3.3 Phosphodiesterase Inhibitors1.3.4 Interleukin Blockers1.3.5 Others1.4 Market Segment by Application1.4.1 Global Psoriasis Treatment Market Share by Application (2018-2025)1.4.2 Oral1.4.3 Tropical1.4.4 Injectable1.5 Study Objectives1.6 Years Considered

2 Global Growth Trends2.1 Production and Capacity Analysis2.1.1 Global Psoriasis Treatment Production Value 2013-20252.1.2 Global Psoriasis Treatment Production 2013-20252.1.3 Global Psoriasis Treatment Capacity 2013-20252.1.4 Global Psoriasis Treatment Marketing Pricing and Trends2.2 Key Producers Growth Rate (CAGR) 2018-20252.2.1 Global Psoriasis Treatment Market Size CAGR of Key Regions2.2.2 Global Psoriasis Treatment Market Share of Key Regions2.3 Industry Trends2.3.1 Market Top Trends2.3.2 Market Drivers

3 Market Share by Manufacturers3.1 Capacity and Production by Manufacturers3.1.1 Global Psoriasis Treatment Capacity by Manufacturers3.1.2 Global Psoriasis Treatment Production by Manufacturers3.2 Revenue by Manufacturers3.2.1 Psoriasis Treatment Revenue by Manufacturers (2013-2018)3.2.2 Psoriasis Treatment Revenue Share by Manufacturers (2013-2018)3.2.3 Global Psoriasis Treatment Market Concentration Ratio (CR5 and HHI)3.3 Psoriasis Treatment Price by Manufacturers3.4 Key Manufacturers Psoriasis Treatment Plants/Factories Distribution and Area Served3.5 Date of Key Manufacturers Enter into Psoriasis Treatment Market3.6 Key Manufacturers Psoriasis Treatment Product Offered3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type4.1 Production and Production Value for Each Type4.1.1 TNF Inhibitors Production and Production Value (2013-2018)4.1.2 Phosphodiesterase Inhibitors Production and Production Value (2013-2018)4.1.3 Interleukin Blockers Production and Production Value (2013-2018)4.1.4 Others Production and Production Value (2013-2018)4.2 Global Psoriasis Treatment Production Market Share by Type4.3 Global Psoriasis Treatment Production Value Market Share by Type4.4 Psoriasis Treatment Ex-factory Price by Type

5 Market Size by Application5.1 Overview5.2 Global Psoriasis Treatment Consumption by Application

6 Production by Regions6.1 Global Psoriasis Treatment Production (History Data) by Regions 2013-20186.2 Global Psoriasis Treatment Production Value (History Data) by Regions6.3 United States6.3.1 United States Psoriasis Treatment Production Growth Rate 2013-20186.3.2 United States Psoriasis Treatment Production Value Growth Rate 2013-20186.3.3 Key Players in United States6.3.4 United States Psoriasis Treatment Import & Export6.4 Europe6.4.1 Europe Psoriasis Treatment Production Growth Rate 2013-20186.4.2 Europe Psoriasis Treatment Production Value Growth Rate 2013-20186.4.3 Key Players in Europe6.4.4 Europe Psoriasis Treatment Import & Export6.5 China6.5.3 Key Players in China6.5.2 China Psoriasis Treatment Production Value Growth Rate 2013-20186.5.3 Key Players in China6.5.4 China Psoriasis Treatment Import & Export6.6 Japan6.6.1 Japan Psoriasis Treatment Production Growth Rate 2013-20186.6.2 Japan Psoriasis Treatment Production Value Growth Rate 2013-20186.6.3 Key Players in Japan6.6.4 Japan Psoriasis Treatment Import & Export6.7 Other Regions6.7.1 South Korea6.7.2 India6.7.3 Southeast Asia

7 Psoriasis Treatment Consumption by Regions7.1 Global Psoriasis Treatment Consumption (History Data) by Regions7.2 North America7.2.1 North America Psoriasis Treatment Consumption by Type7.2.2 North America Psoriasis Treatment Consumption by Application7.2.3 North America Psoriasis Treatment Consumption by Countries7.2.4 United States7.2.5 Canada7.2.6 Mexico7.3 Europe7.3.1 Europe Psoriasis Treatment Consumption by Type7.3.2 Europe Psoriasis Treatment Consumption by Application7.3.3 Europe Psoriasis Treatment Consumption by Countries7.3.4 Germany7.3.5 France7.3.6 UK7.3.7 Italy7.3.8 Russia7.4 Asia Pacific7.4.1 Asia Pacific Psoriasis Treatment Consumption by Type7.4.2 Asia Pacific Psoriasis Treatment Consumption by Application7.4.3 Asia Pacific Psoriasis Treatment Consumption by Countries7.4.4 China7.4.5 Japan7.4.6 Korea7.4.7 India7.4.8 Australia7.4.9 Indonesia7.4.10 Thailand7.4.11 Malaysia7.4.12 Philippines7.4.13 Vietnam7.5 Central & South America7.5.1 Central & South America Psoriasis Treatment Consumption by Type7.5.2 Central & South America Psoriasis Treatment Consumption by Application7.5.3 Central & South America Psoriasis Treatment Consumption by Countries7.5.4 Brazil7.6 Middle East and Africa7.6.1 Middle East and Africa Psoriasis Treatment Consumption by Type7.6.2 Middle East and Africa Psoriasis Treatment Consumption by Application

8 Company Profiles8.1 Novartis International AG8.1.1 Novartis International AG Company Details8.1.2 Company Description and Business Overview8.1.3 Production and Revenue of Psoriasis Treatment8.1.4 Psoriasis Treatment Product Introduction8.1.5 Novartis International AG Recent Development8.2 Johnson & Johnson8.2.1 Johnson & Johnson Company Details8.2.2 Company Description and Business Overview8.2.3 Production and Revenue of Psoriasis Treatment8.2.4 Psoriasis Treatment Product Introduction8.2.5 Johnson & Johnson Recent Development8.3 Pfizer Inc.8.3.1 Pfizer Inc. Company Details8.3.2 Company Description and Business Overview8.3.3 Production and Revenue of Psoriasis Treatment8.3.4 Psoriasis Treatment Product Introduction8.3.5 Pfizer Inc. Recent Development8.4 Merck and Co. Inc.8.4.1 Merck and Co. Inc. Company Details8.4.2 Company Description and Business Overview8.4.3 Production and Revenue of Psoriasis Treatment8.4.4 Psoriasis Treatment Product Introduction8.4.5 Merck and Co. Inc. Recent Development8.5 AbbVie and Amgen8.5.1 AbbVie and Amgen Company Details8.5.2 Company Description and Business Overview8.5.3 Production and Revenue of Psoriasis Treatment8.5.4 Psoriasis Treatment Product Introduction8.5.5 AbbVie and Amgen Recent Development8.6 Eli Lilly8.6.1 Eli Lilly Company Details8.6.2 Company Description and Business Overview8.6.3 Production and Revenue of Psoriasis Treatment8.6.4 Psoriasis Treatment Product Introduction8.6.5 Eli Lilly Recent Development

9 Market Forecast: Production Side9.1 Production and Production Value Forecast9.1.1 Global Psoriasis Treatment Capacity, Production Forecast 2018-20259.1.2 Global Psoriasis Treatment Production Value Forecast 2018-20259.2 Psoriasis Treatment Production and Production Value Forecast by Regions9.2.1 Global Psoriasis Treatment Production Value Forecast by Regions9.2.2 Global Psoriasis Treatment Production Forecast by Regions9.3 Psoriasis Treatment Key Producers Forecast9.3.1 United States9.3.2 Europe9.3.3 China9.3.4 Japan9.3.5 Other Regions9.4 Forecast by Type9.4.1 Global Psoriasis Treatment Production Forecast by Type9.4.2 Global Psoriasis Treatment Production Value Forecast by Type

10 Market Forecast: Consumption Side10.1 Consumption Forecast by Application10.2 Psoriasis Treatment Consumption Forecast by Regions10.3 North America Market Consumption Forecast10.3.1 North America Psoriasis Treatment Consumption Forecast by Countries 2018-202510.3.2 United States10.3.3 Canada10.3.4 Mexico10.4 Europe Market Consumption Forecast10.4.1 Europe Psoriasis Treatment Consumption Forecast by Countries 2018-202510.4.2 Germany10.4.3 France10.4.4 UK10.4.5 Italy10.4.6 Russia10.5 Asia Pacific Market Consumption Forecast10.5.1 Asia Pacific Psoriasis Treatment Consumption Forecast by Countries 2018-202510.5.2 China10.5.3 Japan10.5.4 Korea10.5.5 India10.5.6 Australia10.5.7 Indonesia10.5.8 Thailand10.5.9 Malaysia10.5.10 Philippines10.5.11 Vietnam10.6 Central & South America Market Consumption Forecast10.6.1 Central & South America Psoriasis Treatment Consumption Forecast by Country 2018-202510.6.2 Brazil10.7 Middle East and Africa Market Consumption Forecast10.7.1 Middle East and Africa Psoriasis Treatment Consumption Forecast by Countries 2018-202510.7.2 Middle East and Africa10.7.3 GCC Countries10.7.4 Egypt10.7.5 South Africa

11 Value Chain and Sales Channels Analysis11.1 Value Chain Analysis11.2 Sales Channels Analysis11.2.1 Psoriasis Treatment Sales Channels11.2.2 Psoriasis Treatment Distributors11.3 Psoriasis Treatment Customers

12 Opportunities & Challenges, Threat and Affecting Factors12.1 Market Opportunities12.2 Market Challenges12.3 Porters Five Forces Analysis12.4 Macroscopic Indicator12.4.1 GDP for Major Regions12.4.2 Price of Raw Materials in Dollars: Evolution

13 Key Findings

14 Appendix14.1 Research Methodology14.1.1 Methodology/Research Approach14.1.1.1 Research Programs/Design14.1.1.2 Market Size Estimation14.1.1.3 Market Breakdown and Data Triangulation14.1.2 Data Source14.1.2.1 Secondary Sources14.1.2.2 Primary Sources14.2 Author Details14.3 Disclaimer

Request Customization of Report : https://www.qyresearch.com/customize-request/form/703094/global-psoriasis-treatment-industry-research-report-growth-trends-and-competitive-analysis-2018-2025

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

This post was originally published on Info Street Wire

Go here to read the rest:

Psoriasis Treatment Market 2019 Industry Size, Shares and Upcoming Trends 2025 - Info Street Wire

The intense rivalry between the leading psoriasis treatment providers across the world characterizes the global psoriasis treatment market. According to Transparency Market Research (TMR), a leading market research and intelligence firm, thepsoriasis treatment marketdemonstrates a high competitive and fragmented vendor landscape. Led by AbbVie, LEO Pharma, AstraZeneca, Biogen, and Pfizer, this market has gained significant momentum due to the competition among these players. To sustain in this competitive environment, these companies are relying on new product launches and research and development of their existing product portfolio.

TMR evaluates the opportunity in the global psoriasis market to rise at a CAGR of 5.10% during the period from 2016 to 2024. The main products in this market are TNF inhibitors, interleukin blockers, and vitamin D analogues or combinations. Due to their efficiency and safety, the demand for TNF inhibitors has been relatively higher than other products available in this market. On the other hand, interleukin blockers are gaining momentum due to their ability to act by targeting the proteins, which will raise their demand in the near future, states the research report.

Request a PDF Sample of Psoriasis Treatment MarketReport

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17960

Rising Prevalence of Psoriasis to Support Market

The global psoriasis treatment market derives growth from a number of factors. The most important one among them is the alarming rise in the prevalence of psoriasis among people across the world. Psoriasis is an autoimmune disease, which means it can only be controlled and not cured completely. It also indicates that a person suffering from psoriasis needs to be on medication throughout his/her life, creating an opportune situation for psoriasis treatment providers.

Companies active in this market are increasingly being involved in research and developments to innovate and introduce new products for the treatment of psoriasis. At present, there is a strong pipeline of products related to psoriasis treatment across the world. The speedy approvals of these novel drugs and therapies by the U.S. FDA is further supporting the growth of the worldwide psoriasis treatment market. Additionally, the continued infrastructural development in the medical and healthcare sector, especially in emerging countries, leading to an easy access to better medical services, will propel this market in the years to come.

Request for a Discount on Psoriasis Treatment Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=17960

Increase in Patient Pool to Boost North America Psoriasis Treatment Market

In terms of the geography, the worldwide psoriasis treatment market registers its presence across Latin America, North America, Europe, Middle East and Africa, and Asia Pacific. With constantly rising patient pool, North America has emerged as the leading regional psoriasis treatment market. Researchers expect this regional market to remain on top over the next few years. A number of well-established psoriasis treatment providers have their headquarters in the U.S. and they consider North America as their main market. This factor is likely to have a positive influence on the North America psoriasis treatment in the years to come.

Currently, Europe is also registering a decent growth in its psoriasis treatment market. However, it will witness a decline in the sale over the forthcoming years, following an intense challenge from biosimilars. Among others, Asia Pacific and Latin America are expected to display promising opportunities for market players in the near future, thanks to their untapped status. The increasing awareness among people regarding the treatment of psoriasis in emerging Asian and Latin American countries will boost the growth of their respective regional markets for psoriasis treatments in the forthcoming years, notes the markets study.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving method-ologies and leveraging existing data repositories.TMR believes that unison of solutions for clients-specific problems with right methodology of re-search is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY 12207United StatesTel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email:[emailprotected]Website:http://www.transparencymarketresearch.comBlog:https://theglobalhealthnews.com/

This post was originally published on Market Reports Observer

Read the rest here:

Psoriasis Treatment Market Key Manufacturers, Development Trends and Competitive Analysis - Market Reports Observer

I have never had any skin problems before in all my life. Then I was put on a beta-blocker drug and one of the side effects I got was some patches on my body and scalp. The doctor said it was psoriasis. What is that?

Psoriasis is actually a common skin condition.

It develops when the life cycle of your skin cells is speeded up, causing them to die and build up on your skin surface quickly.

These extra skin cells form scales on your skin, as well as red patches, which can be itchy, and even painful.

What is the difference between psoriasis and eczema?

Psoriasis has well-defined, thick, red and scaly patches, especially at your elbows and knees.

The patches can also appear on your face, buttocks, palms, soles and scalp.

Your skin is thicker and more inflamed than those with eczema.

Eczema also causes your skin to be red and inflamed. It is sometimes scaly, but it can also be oozing or crusty.

There may be swelling or dark, leathery patches.

Eczema tends to appear in the crooks (or inner parts) of your knees and elbows, i.e. the parts of your body that bend.

However, it can also appear on your neck, wrists, ankles and other places on babies.

Eczema is more commonly associated with children.

The itching in eczema is also more intense than in psoriasis.

Stress is one of the major factors that contribute to the triggering or worsening of psoriasis. VisualHunt.com

I heard that there are many types of psoriasis. Is this true?

Yes, everyone has different manifestations of psoriasis.

We know already that the distinct common feature is red, scaly patches on your skin due to overproduction of skin cells.

Plaque psoriasis is the commonest form. The red, silvery scaly patches are called plaques.

These plaques can occur on any part of your body, including inside your mouth and on your genitals.

There is also nail psoriasis. Obviously, this affects your fingernails and toenails, and can cause abnormal nail growth, pits (little holes) and discolouration of your nails.

Your nails can also separate from your nail bed, or even crumble entirely.

When the psoriasis patches are not formed in plaques, but in waterdrop-shaped lesions instead, it is called guttate psoriasis.

This affects young children and young adults. It is usually triggered by a bacterial infection such as a sore throat.

The skin lesions are not as thick as plaque psoriasis.

Then there is inverse psoriasis, which affects the skin on your armpits, groin, under your breasts or around your genitals.

These become worse with friction or sweating, like if you wear tight clothing.

This one has a correlation with fungal infections.

One uncommon type is pustular psoriasis. This one has pus-filled blisters on top of your red skin.

It can get quite bad because it may be associated with fever, severe itching and diarrhoea.

The rarest type is also one of the worst due to the way it looks, called erythrodermic psoriasis.

This one covers your entire body with a red rash that peels easily. It can also unfortunately itch or burn badly.

I know a relative with psoriasis who also has joint pain. Does psoriasis give rise to joint pain?

Some psoriasis patients can also suffer from joint pain due to their condition. TPNYes, this is called psoriatic arthritis. It does not happen in all psoriatic cases.

It is not as bad as rheumatoid arthritis, but can be severe as well.

This type of joint pain affects any joint. The underlying issue is inflammation and erosion of your joints.

This leads to stiffness, swelling and worsening deformity.

What is the cause of psoriasis?

No one really knows, but it is believed to be an autoimmune disease.

Your white blood cells called T lymphocytes and neutrophils attack healthy skin cells by mistake.

They travel to your skin, causing your blood vessels to dilate and your skin cells to overproduce.

That is why you have redness, swelling, and even pus it is as though your body is fighting off a skin infection.

There is also a genetic element in psoriasis. If your parents had psoriasis, you are more likely to have it too.

Is there anything that triggers psoriasis? I was told it was because of the medication I took.

Many things can trigger psoriasis, especially if you have an underlying genetic predisposition for it already.

We have already discussed that sore throats caused by bacteria, especially Streptococcus, can trigger it.

So can skin infections and injuries, like burns, sunburns, bites and cuts.

Stress can also trigger psoriasis. So can smoking and alcohol.

The types of medicines that can trigger it include beta-blockers, used for high blood pressure; lithium, used for psychotic disorders; and drugs used for malaria.

There is unfortunately no cure for psoriasis, but you can moisturise your skin, give up smoking and alcohol, stop taking those medications giving you psoriasis, and manage your stress levels, to help manage your condition.

Dr YLM graduated as a medical doctor, and has been writing for many years on various subjects such as medicine, health, computers and entertainment. For further information, email starhealth@thestar.com.my. The information contained in this column is for general educational purposes only. Neither The Star nor the author gives any warranty on accuracy, completeness, functionality, usefulness or other assurances as to such information. The Star and the author disclaim all responsibility for any losses, damage to property or personal injury suffered directly or indirectly from reliance on such information.

We're sorry, this article is unavailable at the moment. If you wish to read this article, kindly contact our Customer Service team at 1-300-88-7827. Thank you for your patience - we're bringing you a new and improved experience soon!

Article type: metered

User Type: anonymous web

User Status:

Campaign ID: 7

Cxense type: free

User access status: 3

Read the original here:

Thick, scaly patches appearing on your skin? It's psoriasis - The Star Online

Psoriasis is a chronic autoimmune disorder affecting the skin and anyone, including babies and young children, can develop it. Although psoriasis does occur in infants, it is uncommon.

The disease speeds up the life cycle of skin cells, causing them to build up too quickly on the skins surface. The resulting extra skin cells can create thick, silver or white scales and patches that are dry, red, itchy, and sometimes painful.

Contents of this article:

Plaque psoriasis may appear on the elbows, scalp and lower back.

Infant is considered a rare condition. In fact, children under the age of 10 are to develop psoriasis as people between the ages of 15 and 35.

While infants and very young children can develop psoriasis, it can only be diagnosed after close observation.

If an infant does have psoriasis, it tends to develop in the diaper area. This makes it particularly easy to confuse with more common rashes and it is far more likely that the baby has developed one of these that will go away with time and proper treatment.

There are of psoriasis that people can develop, including infants:

Plaque psoriasis is the most common form in children, adults, and babies. Plaque psoriasis causes areas of raised, red patches covered with a silvery-white buildup of dead skin cells.

The patches occur mostly on the elbows, scalp, lower back, and knees. The often itchy and painful patches can crack and bleed.

Guttate psoriasis appears as small, dot-like lesions on the skins surface and is the second most common type of psoriasis in babies, children, and adults. Guttate psoriasis often starts in children and young adults and can be triggered by strep infections.

Pustular psoriasis appears as red skin surrounding white pustules. The consists of white blood cells.

Like any psoriasis, it is not an infection and is not contagious. Pustular psoriasis mostly occurs on hands and feet, but it can occur on any part of the body.

Nail psoriasis affects fingernails and toenails, causing pitting, abnormal nail growth, and color changes.

Psoriasis that affects the nails may cause them to become loose and separate from the nail bed. Severe cases may cause the nail to crumble.

Scalp psoriasis, as the name suggests, forms on the scalp and appears as red, itchy areas with silver or white scales that often extend beyond the hairline.

A person with scalp psoriasis will likely notice flakes of dead skin in the hair and on their shoulders after scratching the scalp.

In infants this should not be confused with seborrheic dermatitis (cradle cap), which appears as greasy, yellowish scales, or a crust on the scalp.

Inverse psoriasis may appear to be shiny and smooth will often appear alongside another form of psoriasis.

Inverse psoriasis appears as very red lesions around areas of body folds, such as in the groin, under the arms, and behind the knees. Often its appearance is smooth and shiny.

A person with inverse psoriasis often has another form of psoriasis happening at the same time elsewhere on the body.

Erythrodermic psoriasis is a severe, life-threatening form of psoriasis marked by widespread, fiery redness over much of the body. Erythrodermic psoriasis can cause severe itching, pain, and cause the skin to come off in large sections.

It is very rare, most frequently occurring in people who have unstable plaque psoriasis.

Infant psoriasis has the same cause as psoriasis in other age groups, but is often triggered by an upper respiratory infection, or .

As with other autoimmune diseases, researchers believe that certain sets of genes and abnormalities in those genes may cause psoriasis.

Doctors and researchers have no way of predicting who will develop psoriasis. The disease affects people of all ethnicities. However, a baby is more likely to develop psoriasis if there is a family history of it.

Psoriasis in infants can be extremely hard to diagnose because of the symptoms similarity to other, much more common infant skin conditions.

The most common symptom is a red rash that may appear to have scaly, white patches. Other symptoms may include:

As said, infant psoriasis is a very rare condition. If an infant has a rash, it is likely to be a more common skin rash such as .

Other rashes that babies are prone to include the following:

The only true way to determine if an infant has psoriasis or another skin condition is through careful observation. Unlike other rashes, psoriasis eventually scales over, with patches of white or silver over the red.

Psoriasis in infants may be concentrated on the skin around the knees, face, scalp, elbows, and neck while other rashes may occur anywhere.

Light therapy may be offered as a treatment for infant psoriasis.

If a rash appears on a babys skin and remains for several days despite the use of over-the-counter creams and treatments, caregivers should consult a doctor to check the rash.

For a doctor to diagnose psoriasis, they will need to observe the rash for some time.

Once diagnosed, however, psoriasis has many treatment options, which may include the following:

Psoriasis is an unpredictable and lifelong condition. It is most often associated with periods when symptoms become more severe and periods when they improve. Some people see a complete improvement while others always have some symptoms present.

Psoriasis can typically be managed with proper medical attention.

Written by Jenna Fletcher

See the original post here:

Medical News Today: Does my baby have psoriasis? Symptoms and treatment - Stock Daily Dish

Psoriatic arthritis is a type of chronic arthritis that sometimes occurs in people with psoriasis. It is most common in people between the ages of 30 and 50, but can begin as early as childhood. The disease affects men and women equally.

is a condition that causes the cells of the immune system to attack normal skin cells. As a result, it causes scaly red and white patches to form that can be itchy and uncomfortable.

Some people with psoriasis will also develop psoriatic (PsA), where the immune system also attacks the joints. Both conditions cause episodes where the symptoms worsen, also known as a flare. Most of the time the symptoms will lessen between flares.

This article will look at the outlook for people with PsA, examining how the disease progresses and how it may affect peoples quality of life.

Contents of this article:

PsA symptoms may include painful, swollen joints and swollen fingers and toes.

In most cases, people are diagnosed with psoriasis before developing PsA. However, it is possible to develop joint and pain before being diagnosed with psoriasis.

Symptoms of PsA may include:

A person with these symptoms and who has a medical history of psoriasis should see their doctor promptly. Because the symptoms tend to worsen and get better, it can sometimes be difficult for the doctor to diagnose.

It is important for people to mention and discuss the diagnosis of psoriasis so that the doctor can evaluate the pain appropriately.

It can affect the joints on one or both sides of the body, and it can vary in severity from person to person. In some people, PsA is mild and causes little pain. In others, it can cause severe pain that makes it difficult to carry out normal activities.

PsA can affect different parts of the body in different ways, including the following:

It is believed that inflammation associated with PsA can eventually cause joint damage later on. Early diagnosis and treatment is essential to reduce the risk as much as possible and improve comfort.

Doctors know that people with PsA may be at risk for other diseases that can lower their life expectancy. These diseases include and . Psoriasis is also linked to and mood changes, such as and .

Some research has suggested that people with psoriasis and PsA have a slightly increased risk of cancer. that the increased risk wasnt related to any of the medications used to treat the disease. This means that the cancer risk may be related to the disease itself, and not the treatment.

However, a suggests that experts are now unsure that life expectancy is affected. This study also does not suggest that the risk of cancer is increased.

It is important for people with psoriasis and PsA to maintain a healthy weight and be routinely screened for cancer and heart disease. Prompt treatment of and high can help to minimize the risk of developing further complications.

Discussing pain levels with a healthcare professional is important for people with PsA to ensure they receive the correct pain treatment plan.

The biggest quality of life concern for people with PsA is pain and discomfort. The joint pain and stiffness from the arthritis can range from mild to quite severe.

In addition, the scaly patches of skin associated with psoriasis can be very itchy and uncomfortable, even painful. Without appropriate treatment of the arthritis the disease can be debilitating.

Having an honest conversation with the doctor about pain levels is an important measure for people with PsA. There are many different options for pain management, and sometimes people with PsA may have to try several different options before finding one that works.

Keeping a pain journal can be helpful to people with PsA. This includes keeping track of daily pain levels, activities that worsen pain, and measures that help to relieve it. Sharing this journal with the doctor can help them put together a personal pain treatment plan.

Staying active can help to relieve stiff joints and muscle weakness. Mild exercise, such as , swimming, and gentle stretching can be especially beneficial for people with painful or swollen joints. Physical and occupational therapy can also sometimes be helpful.

In addition to pain management strategies and lifestyle changes, there are many different medication options available for people with PsA. Treatment selection depends on the level of pain, stiffness, and disability that the person is experiencing.

In some mild cases, simple (NSAIDs), such as ibuprofen or naproxen, are effective.

If NSAIDs are not effective for managing a patients pain, there are other options, including:

Other medications that block different parts of the immune system are also being used for PsA now as well.

Long-term pain can become very difficult for people to manage. In many cases, PsA is associated with depression, anxiety, , and difficulty coping.

Having family support can be very important when dealing with PsA. Attending support groups or seeing a counselor or therapist can also help people to learn additional coping skills.

Written by Nicole Galan

Read the original post:

Medical News Today: Prognosis of psoriatic arthritis: Progression and outlook - Stock Daily Dish

Psoriasis is a chronic condition that results in the formation of scaly white and red patches on the skin. These areas of abnormal skin can be itchy and uncomfortable.

According to the American College of Rheumatology, around of people with will develop a type of inflammatory , known as psoriatic arthritis (PsA). Its possible, however, for someone without the skin changes of psoriasis to develop PsA, especially if someone else in their family has the disease.

Contents of this article:

The symptoms of psoriasis are caused by immune system cells abnormally attacking healthy skin and joint tissue. This results in , swelling, and pain.

Doctors arent sure why the immune system in some people attacks healthy tissue, although they believe genetics may play a role. This is because psoriasis and PsA tend to run in families.

In addition, environmental factors may also play a role. Injury, infection, or exposure to an environmental trigger can bring on PsA, especially in people with a family history of the disease.

People with PsA may have symptoms that come and go. The period of time when the symptoms worsen is known as a flare and tends to be triggered by something specific.

The symptoms of PsA may flare up if triggered by stress, exposure to cigarette smoke, or a host of other factors.

Common triggers include:

Understanding what triggers PsA flares is essential to helping prevent them. Keeping a journal and recording information about what has happened before a PsA flare may help.

A person with PsA should keep an eye out specifically for these common triggers, or other factors that might be causing the symptoms. There are online trackers and apps available, but even just a simple pen and paper journal may be useful.

Sharing this information with a doctor can help identify effective treatments or simple lifestyle changes that could improve symptoms.

There are that have been associated with developing PsA:

The symptoms of PsA vary from person to person and can range from very mild to severe. They may include:

PsA can affect any joint, but is most common in the joints of the fingers, toes, lower back, wrists, knees, or ankles.

Both psoriasis and PsA cause episodes where the symptoms worsen, also known as flares. Most of the time, the symptoms will lessen between flares.

In most cases, a person with PsA will be diagnosed with psoriasis before developing the joint stiffness and pain associated with arthritis. However, some people will have symptoms of the arthritis before being diagnosed with psoriasis.

Psoriatic spondylitis may lead to stiffness and pain in the neck.

There are five different patterns of PsA that have been identified, based on the number and types of joints involved. They are:

A majority of cases are diagnosed as following the oligoarticular pattern of PsA. In addition, affected joints tend not to be equal on both sides of the body.

There is no single test for PsA. Instead, a doctor will need to rule out the presence of other conditions that cause the same symptoms, by using the following methods:

Symptoms of PsA can appear and then disappear before someone can get to the doctor, making diagnosis difficult. Its not uncommon for a person to have a few flares before the disease is diagnosed.

Anyone with a history of psoriasis and joint pain or swelling should see their doctor promptly. They should be sure to mention that they have psoriasis so that they can be properly evaluated.

Pain management is usually a major concern for people with PsA. There are many different options available and it can sometimes take a bit of trial and error before the best option is found.

Mild exercise and staying active can help to relieve painful joints and stiff muscles. Particularly effective exercises for patients with PsA include and swimming. Its important for people to find an activity that is comfortable and then to stick with it.

Mild exercise, such as swimming and yoga, can help people with PsA effectively manage pain.

There are several different medications that can be used to treat symptoms and prevent joint damage in people with PsA. The doctor will select a medication based on the amount of pain, swelling and stiffness that the patient has.

Options include:

Some of these drugs can have serious side effects and are not appropriate for everyone. It is important for people with PsA to see their doctor regularly, or call with any concerns.

Written by Nicole Galan

Read more from the original source:

Medical News Today: Causes of psoriatic arthritis: Triggers and risk factors - Stock Daily Dish

Patients with psoriasis have an increased risk of cancer and cancer-related mortality, according to a study published in JAMA Dermatology.

Researchers conducted a systematic review and meta-analysis of observational studies from MEDLINE, Embase, MEDLINE in Process, Cochrane Central Register, Web of Science, and LILACS through November 2017. They included cohort and case-control studies that provided estimates of the risk of cancer incidence or cancer mortality associated with psoriasis.

A total of 58 studies were included, with quality varying for the incidence and the mortality studies.

Severe psoriasis (relative risk [RR] = 1.22; 95% CI, 1.08-1.39) and all severities of psoriasis (RR=1.18; 95% CI, 1.06-1.31) were associated with an overall increased risk of cancer. These associations were observed among the following cancer types:

Overall cancer mortality risk was higher in patients with severe psoriasis (RR=1.22; 95% CI, 1.08-1.38). The following cancers were associated with increased mortality among patients with severe psoriasis:

The researchers noted that the heterogeneity of estimates was often very high despite stratification. Reduced risk was observed in studies that adjusted estimates for smoking, alcohol consumption, and obesity.

Future research examining specific lifestyle factors, treatments, and the inflammatory processes that contribute to psoriasis may help provide additional information on the underlying mechanisms for the apparent increased cancer risk, the researchers concluded.

Go here to see the original:

Psoriasis Associated With Increased Risk of Cancer and Mortality - DocWire News

A drug made by Johnson & Johnson for psoriasis that is one of the biggest revenue generators in its portfolio could be under threat in the future following the success of a new competitor in a Phase III study.

Brussels-based UCB said Thursday that results of its BE VIVID study showed that its antibody, bimekizumab, was superior in its efficacy against J&Js Stelara (ustekinumab) in adult patients with moderate-to-severe chronic plaque psoriasis.

The company did not disclose the full results, which it said would be presented in due course, but stated that the trial met the primary endpoint of showing at least a 90 percent improvement in psoriasis area and severity index or PASI90 and an investigator global assessment score of clear or almost clear after 16 weeks. The safety profile was consistent with the Phase II BE ABLE studies.

BE VIVID randomizes patients to receive bimekizumab for one year, Stelara for one year with placebo at certain time points to maintain blinding or placebo for 16 weeks followed by bimekizumab for the remainder of the study period. Bimekizumab is an IgG1 antibody tat neutralizes IL-17A and IL-17F, two key cytokines that drive inflammation.

These encouraging first results provide strong evidence that bimekizumab has the potential to raise the bar for achieving skin clearance rates in patients, investigator Dr. Mark Lebwohl of New Yorks Icahn School of Medicine said in a statement. Achieving clear skin is of critical importance in positively impacting the lives of psoriasis patients.

Stelara, which was approved in 2009, was J&Js second largest product in 2018, accounting for about 6.3 percent of its total sales for the year, with global sales of about $5.2 billion, according to its 2018 annual report. U.S. patents for Stelara are expected to expire in 2023 due to a patent term extension, followed by expiration in Europe the following year. The companys top-selling product is the autoimmune disease drug Remicade (infliximab), which had sales of $5.3 billion and which already has biosimilar competitors.

In the Phase IIb BE ABLE 1 trial, which randomized patients to various dose levels of bimekizumab or placebo, patients treated with the drug showed a statistically significant dose-dependent response for PASI90, with 46.2-79.1 percent of patients achieving it, compared with 0 percent in the placebo arm. In addition, 27.9-60 percent of bimekizumab-treated patients achieved PASI100, also compared with 0 percent in the placebo arm. Treatment-emergent adverse events occurred among 126 of the 208 patients treated with bimekizumab, compared with 15 of 42 who received placebo.

Photo: juststock, Getty Images

Original post:

UCB psoriasis drug beats J&J's second top-selling product in Phase III study - MedCity News

For a pharma company with about $5 billion in revenue, a couple of respectably sized blockbuster drugs on the market and some high-profile partners like Amgen, Belgiums UCB has kept an unusually low profile on the pipeline side of things over the years.

Until now.

Just days after striking a $2.1 billion deal to buy Ra Pharmaceuticals and its C5 rival to Soliris, UCB is posting positive top-line Phase III results for a dual IL-17 inhibitor that its steering into one of the most competitive commercial spaces in the industry. And despite plenty of obvious challenges as they struggle to roll out Evenity with Amgen and patent expirations loom on its franchise drugs, including Cimzia, the company just may be ready to tackle some of the biggest players on the planet.

In their first of 3 Phase III studies for bimekizumab, researchers touted top-line wins on statistically significant results on clearing plaque psoriasis, including a victory over J&Js IL-23 contender Stelara on key endpoints. The drug targets both IL-17A and IL-17F, a modification on the IL-17A strategy laid out for Taltz (Eli Lilly) and Cosentyx (Novartis). And the new group also includes J&Js Tremfya and AbbVies Skyrizi.

We dont know the PASI90 and IGA scores but UCB knows that with the kind of heavyweight competition it faces with Novartis and others, marginal gains for patients wont stack up. So well be watching for the hard numbers. And theres another head-to-head with Cosentyx that will play a big role in pushing up analysts projections on peak sales, which currently fall well short of blockbuster status.

UCB hasnt exactly been in the spotlight for the last few years, but its in a position now that the company has to win some respect in R&D, with blockbuster projects that can keep investors attention at a time the industry is experiencing booming R&D development efforts around the planet.

It hasnt been easy. There was a setback on a lupus drug partnered with Biogen. But there have been some advances, with a deal to buy Proximagens NDA-ready nasal spray therapy USL261, designed as a rescue therapy for acute repetitive seizures, for $150 million in cash and another $220 million in sales and regulatory milestones. There was even a report that the company was kicking the deflated tires at Acorda, though nothing came of that.

Late last year UCB also committed to spend up to 200 million on a new R&D hub in the UK.

That may not translate into a lot of excitement right now, but theyre trying. And theres a subtle promise that more deals may be in the works.

Social image: UCB

Read the rest here:

UCB tries to win some respect in the crowded psoriasis market with a dual IL-17 approach and it won't be easy - Endpoints News

Text size

The drugmaker Eli Lilly has struggled this year, with the stock down 6.7% in 2019. That is well behind the broader S&P 500 health-care sector, which is up 6%, and the broader S&P 500, which is up 19.9% since the start of the year.

The company will make its case on Wednesday morning when it unveils its third-quarter earnings. Lilly has scheduled a conference call for 9 a.m. ET.

The earnings report comes weeks after a double-dose of good news for Eli Lilly (ticker: LLY). Earlier this month, the Food and Drug Administration approved the companys migraine drug Reyvow, and the company unveiled positive data on its drug Taltz in pediatric patients with plaque psoriasis, all in the space of two days.

Eli Lilly stock trades at 16.9 times its estimated earnings over the next 12 months, slightly below its five-year average of 19.8 times earnings.

Heres a snapshot of investors expectations and recent history.

Wall Street analysts expect earnings of $1.39 per share in the third quarter, according to FactSet, and sales of $5.5 billion.

In a note out October 18, J.P. Morgan analyst Chris Schott wrote that he expected growth on the sale of core products. Strong product trends continue despite competition, Schott wrote.

The companys anti-inflammatory drug Taltz is facing an increasingly crowded field, including AbbVies (ABBV) new drug Skyrizi and other drugs from Novartis (NVS), Celgene (CELG). Still, Schott wrote that Taltz has shown relatively healthy performance despite the Skyrizi launch.

On October 16, Bank of America Merrill Lynch analyst Geoff Meacham issued a Buy rating on Lilly, writing that he viewed the risk/reward profile in Lilly as compelling, and setting a $133 price target on the stock.

The company has reported some promising data in recent months, including a strong response rate for its drug LOXO-292 in some lung cancer patients, and the data on Taltz in pediatric patients with plaque psoriasis.

In July, Lilly reported earnings per share of $1.50, beating Wall Street expectations of $1.45 just slightly. The company attributed the beat to an increase in volume.

Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com

Read the original post:

Eli Lilly Reports Earnings Tomorrow. Heres What to Expect. - Barron's

Kim Kardashian got candid about her battle with psoriasis and dealing with her new psoriatic arthritis diagnosis in a revealing personal essay for sister Kourtney Kardashians wellness site,Poosh.

The reality star spoke about her first outbreak at 25 and detailed the rollercoaster of emotions shes faced in dealing with the chronic skin condition. Kardashian said that shes learned to deal with the patch of skin her right leg that gets the most frequent flare-ups, though it often spreads.

Earlier this year is when it got extremely bad it covered my whole face and a majority of my entire body, she wrote. She also spoke about finding out she suffered from psoriatic arthritis after waking up and not being able to use her hands.

One night, I woke up to use the restroom and I physically couldnt pick up my phone. I thought it was strange but maybe I just slept on my hands weird and I was so tired, I didnt need to be checking my phone at that hour anyway. I fell right back asleep, she said in her essay. I woke up that morning and I still couldnt pick up my phone. I was freaking out I couldnt even pick up a toothbrush, my hands hurt so badly.

At a certain press event, her pain level was so high that she couldnt even get dressed.

I couldnt even get my bra on that day, and I had to have someone dress me because the pain was so unbearable, she said. With the boots I was wearing, my ankles started to feel it in those joints. Thats when I knew it wasnt just an issue in my hands, it was a bone problem.

Kardashian finally sought help and went to the doctor, where she tested positive for rheumatoid arthritis and lupus, which turned out to be a false positive. But it did lead to her diagnosis of psoriatic arthritis.

Its similar to arthritis that can stem from psoriasis and it can come and go. Its still painful and scary, but I was happy to have a diagnosis, she shared.

Kim Kardashian/InstagramKardashian shared a candid photo of her skin condition in March.

These days, Kardashian maintains a plant-based diet and said that shes extremely comfortable with her skin condition.

No matter where it is on my body, sometimes I am fine with showing it off and other times I dont want it to be a distraction, so I cover it up withbody makeup, she said, before signing off with an encouraging message for anyone else struggling with psoriasis.

You cant let it ruin your life or get the best of you. You have to do what you can to make sure you are comfortable but not let it take over, Kardashian said.

Head to Poosh to read more of Kardashians piece.

REAL LIFE. REAL NEWS. REAL VOICES.

Help us tell more of the stories that matter from voices that too often remain unheard.

Read this article:

Kim Kardashian Shares Pic Of 'Extremely Bad' Psoriasis On Her Face - HuffPost

Measurement of drug levels early in treatment with ustekinumab for patients with psoriasis may be able to successfully predict patient response and, therefore, direct a treatment strategy.

The study included 491 British adults with psoriasis who were recruited from the multicenter Biomarkers of Systemic Treatment Outcomes in Psoriasis study as part of the British Association of Dermatologists Biologic and Immunomodulators Register. A total of 853 samples were obtained from the start of treatment.

The researchers measured disease activity using the Psoriasis Area and Severity Index (PASI) score. At least 1 PASI score was collected within the first year of treatment.

Early measured drug levels had a statistically significant association with 6-month response. Within 12 weeks after starting treatment, measured drug levels were associated with PASI75 (75% reduction in PASI score from baseline) 6 months after treatment started. The researchers reported that drug immunogenicity was low, with antidrug antibodies only detected in 17 (3.5%) of the patients.

This finding suggests that adequate drug exposure early in the treatment cycle may be particularly important in determining clinical outcome with ustekinumab, the authors wrote. They did suggest that additional research should focus on pharmacokinetic-pharmacodynamic modeling of the whole time course of response to ustekinumab.

In addition, they noted that further research is needed to confirm the use of therapeutic drug monitoring for ustekinumab.

In an accompanying editorial,2 Andrew Blauvelt, MD, MBA, of Oregon Medical Research Center, pointed out that although there are newer biologics available for psoriasis, there are a subset of patients who do well on older biologics and nonbiologic therapeutic options. The importance of this new study is that it helps identify which patients will respond to older and less expensive therapeutic options.

The results also bring us 1 step closer toward personalized medicine, an ideal type of future medical practice where all therapies would be chosen based on characteristics (eg, genetic, demographic, biologic) unique to a given individual patient, he wrote.Personalized medicine could assure that each chosen medication is tailored for a given patient, thus optimizing chances for therapeutic success.

References

1. Tsakok T, Wilson N, Dand N, et al. Association of serum ustekinumab levels with clinical response in psoriasis [published online September 18, 2019]. JAMA Dermatol. doi: 10.1001/jamadermatol.2019.1783.

2. Blauvelt A. Predicting clinical responses to ustekinumab: progress toward a future of personalized medicine [published online September 18, 2019]. JAMA Dermatol. doi: 10.1001/jamadermatol.2019.2587.

See the original post here:

Early Levels of Ustekinumab May Predict Longer-term Response in Patients With Psoriasis - AJMC.com Managed Markets Network

Kim Kardashian has always been pretty open about living with psoriasis, but in a recent essay she penned for sister Kourtney's lifestyle site, Poosh, she got more real than ever about her journey with the condition.

In the 1000-word article, the 38-year-old mom of four detailed the highs and lows of living with the common skin condition, which she's had for 13 years now. She also shared never-before-seen photos of her psoriasis, including a flare-up on her face. Despite watching her mom, Kris Jenner, struggle with psoriasis growing up, she admitted that she ultimately had no idea what she was in for.

Turns out, her experience has been quite different than Jenner's. "She had it in her scalp and all over her body, and Id see it all the time and remember her going to the tanning salon to try and ease it for me, however, that remedy would burn the areas and cause them to itch, so I always felt helpless," she wrote. "I am the only child my mom passed down her autoimmune issue to. Lucky me, lol," she added.

Kardashian was 25 when she experienced her first psoriasis flare-up, but at the time, she had it treated with a shot of cortisone and it went away for roughly five years. When it came back in her early 30s, it did so with vengeance, and despite trying myriad remedies (i.e. celery juice, countless creams, changing her diet), she said she now just deals with the largely unpredictable flare-ups. "I have learned to live with this spot (on my leg) without using any creams or medication I just deal. Sometimes I cover it up and sometimes I dont. It doesnt really bother me," the Keeping Up With the Kardashian's star wrote.

What's more, she revealed that both times she was pregnant, it went away completely, though it was short-lived. "That was amazing, but then it came back again," she said. "Earlier this year is when it got extremely bad it covered my whole face and a majority of my entire body."

The KKW Beauty founder also shared several photos of her psoriasis in different stages, including what it looks like when it's fully flaring, as well as how it presents when it's healing. No matter what stage it's in, though, Kardashian has come to terms with it: "Ive become extremely comfortable with my psoriasis. No matter where it is on my body, sometimes I am fine with showing it off and other times I dont want it to be a distraction, so I cover it up with body makeup," she explained.

Follow this link:

Kim Kardashian Published an 1000-Word Essay About Her Psoriasis for Poosh - Allure Magazine

Kim Kardashians troubles are more than just skin-deep.

The reality TV star turned business mogul has written a heartfelt essay for Poosh.com in which she expands on her struggle with psoriasis and psoriatic arthritis.

Even though I always grew up with my mom having psoriasis and hearing her talk about her struggle, I really had no idea what my life would be like dealing with an autoimmune disease myself, she begins, explaining that its been 13 years since she first experienced a psoriasis flare-up. I am the only child my mom passed down her autoimmune issue to, she adds. Lucky me, lol.

According to the National Psoriasis Foundation, more than 8 million Americans suffer from the condition.

Kardashian, 38, treated her first psoriasis flare-up with a cortisone shot, conveniently delivered by her then-neighbor, a dermatologist, after which it went away for five years, only to return in her early 30s.

For the past eight years, although the spots are unpredictable, I can always count on my main spot on my right lower leg, which consistently stays flared up, she details, before adding that when I got pregnant both times, it fully went away.

Kardashian described her initial experience with the arthritis side of the disease as first occurring when she was unable to pick up her phone or use a toothbrush. At first she assumed that shed simply overdone a workout, but as the day wore on, I got a bit more movement in my hands, but they really hurt from the inside I felt it in my bones.

I immediately started to cry and felt so lost, Kardashian added, noting soon after she was diagnosed with rheumatoid arthritis and lupus. Her doctor, however, explained that it was possible shed had a false positive, so she came back three days later to discover this was indeed true, and that her pain stemmed from psoriatic arthritis.

Kardashian also outlined about four months before the arthritis diagnosis where she tried everything natural every ointment, cream, serum, and foam you can possibly imagine and everything from the dermatologist, including celery juice and herbal tea.

Today, however, she has become extremely comfortable with my psoriasis.

If you have psoriasis, you cant let it ruin your life or get the best of you. You have to do what you can to make sure you are comfortable but not let it take over I hope my story can help anyone else with an autoimmune disease feel confident that there is light at the end of the tunnel.

Read this article:

Kim Kardashian details her struggle with psoriasis - Page Six

A young mom has been forced to give up work due to the unbearable pain caused by her psoriasis.

Sabrina Speaks, 23, has scaly plaques covering 90 per cent of her body, after developing the same skin condition as Kim Kardashian.

And now Speaks is opening up about her battle with psoriasis in a bid to raise awareness of the crippling autoimmune condition.

In particular, the mother-of-two, from North Carolina, has admitted that her family and motherhood has saved her from complete depression.

Psoriasis has affected my entire life. It is an autoimmune disorder. I want to make more people aware of that, she said.

Basically, it doesnt allow my immune system to work in a way that it should.

I produce skin cells way too quickly and I also have psoriatic arthritis which is an arthritis that ties in with psoriasis in the most severe cases.

The main side effects of my condition are fatigue, pain, swelling, itching, burning, depression and anxiety.

I cant work because of the pain it causes and also the reactions that I get from people seeing it.

While psoriasis isnt a rare condition, the severity of Speaks psoriasis is extreme with docs saying she is one of the worst cases they have seen.

A lot of people have it. It can be brought on by many things. Stress or even a simple cold can start your symptoms straight away, she said.

But a lot of people do not have it as severe as I do, where a lot of treatments dont work.

Heath Franklin / Barcroft Media

Heath Franklin / Barcroft Media

Barcroft Media

Barcroft Media

Barcroft Media

Heath Franklin / Barcroft Media

I am 90 percent or more covered in plaques. Im clearing up a bit now Im taking my injections, but prior to this, I was way more covered from head to toe.

According to my doctor, I am one of the worst cases theyve ever seen.

The hardest part about living with it is how it affects me as a person, how it changes me.

Im unable to be the person I want to be. I want to be running around with my children and doing things in the world without getting stared at, or without feeling pain.

Unfortunately, I just cant.

There is currently no cure for psoriasis, but Sabrina is having injections on a treatment plan to try and ease the pain and the number of plaques she has.

It all started out as just one spot on the back of her head a spot that suddenly turned really itchy and into a crusty patch.

It kept getting worse and worse. At first doctors said it was ringworm, but eventually, we found out it was psoriasis, Speaks added.

In my teenage years, making friends was really hard. A lot of people were like whos that girl that has all that stuff on her skin and why is she always tired? Just so many questions. I endured way too much bullying as a child and teenager.

And as well as the physical pain, Sabrina has a tricky time when out in public and tries her best to cope with the stares and pointing.

Adults are definitely more harsh than children. Children will come up and ask me about it. Whereas adults will just whisper, point, give you dirty looks and stares, she said.

They dont bother to just ask. Its really hurtful. I hope that with certain people reading and watching my story, they wont be that person in the future. To not just me, but to anyone living with a disease or illness.

Despite her crippling pain, Speaks has managed to find happiness in the shape of her husband and two daughters, Sophia and Madison.

My babies are my life, she said.

If Im anything in this world, Im a mother. Thats what I am first and what Ive always wanted to be.

On a daily basis, they drive me bonkers. But they have also improved my condition.

They make me happier, they take a lot of stress away too.

The turning point in my life was definitely having my first daughter, Sophia. The moment I saw her, I knew I had to be more confident for her sake.

Whether that meant me suffering or not.

And Speaks husband, Daniel, 28, added: I would describe Sabrina as a beautiful, loving mother and wife that would do anything for anybody.

Shes got a heart of gold.

When we first met, she told me about her condition. I was just like youre a really nice person and I want to get to you know you better I didnt mind it. We clicked right away.

I try to take good care of her when shes sick. She struggles a lot sometimes, I so want to make sure Im there for her.

Speaks is now focusing her attention on raising more awareness for psoriasis and those who live with similar conditions.

Its so important to raise awareness for this because theres just not enough information out there, she added.

Were tired, were exhausted, were in pain its a lot to handle. I am proud of everything I am trying to do in my life now, despite my condition. I have a loving husband and two wonderful children, so what more could I want?

View post:

Womans psoriasis is worst docs have seen as scaly plaques cover 90% of her body - New York Post